Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
publishing date : 2021 - 09 - 22 tags : Phase 2 save search
Ascendis Pharma A/S Announces Mean Bone Mineral Density (BMD) Data from Phase 2 PaTH Forward Trial Demonstrating Continued Normalization and Stabilization of BMD Z-scores Between 26 and 58 Weeks
Published: 2021-09-22 (Crawled : 21:00) - globenewswire.com
ASND | $145.17 2.16% 2.11% 220K
|
Health Technology
|
| O: 0.48%
H: 7.17%
C: 6.19%
phase 2 bone trial dmd
Rhythm Pharmaceuticals Presents New Data from Phase 2 and 3 Trials Evaluating Setmelanotide in Multiple Rare Genetic Diseases of Obesity at the 59th Annual ESPE Meeting
Published: 2021-09-22 (Crawled : 15:00) - globenewswire.com
RYTM A | $39.945 2.4% 2.34% 410K
|
Health Technology
|
| O: 2.7%
H: 0.85%
C: -2.56%
disease obesity phase 2 genetic trials trial setmelanotide rare
National Institute of Health Awards SINTX Technologies Phase 1 Grant for SN-PEEK 3D Printed Spinal Implants
Published: 2021-09-22 (Crawled : 13:00) - globenewswire.com
SINT | $0.036 -5.26% -5.56% 34M
|
Health Technology
|
| O: -0.81%
H: 5.69%
C: 5.69%
implant phase 1 phase 2 phase 3 granted grant
Kintara Reports Topline Results from Phase 2 Clinical Study of VAL-083 as Adjuvant Therapy for Newly-Diagnosed GBM Patients
Published: 2021-09-22 (Crawled : 12:00) - prnewswire.com
KTRA | $0.1309 14.52% 12.68% 7.5M
|
Distribution Services
|
| O: 2.27%
H: 13.33%
C: -8.15%
phase 2 therapy results topline
Clover's COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest
Published: 2021-09-22 (Crawled : 12:00) - biospace.com/
DVAX | $11.75 -0.76% -0.77% 1.4M
|
Health Technology
|
| O: 6.33%
H: 30.76%
C: 18.92%
covid phase 2 phase 2/3 vaccine trial
Arcturus Therapeutics Announces Approval from Vietnam Ministry of Health to Proceed into Phase 2 and Phase 3a for ARCT-154, Next Generation STARR™ mRNA Vaccine Targeting SARS-CoV-2 Delta Variant and Other Variants of Concern
Published: 2021-09-22 (Crawled : 12:00) - biospace.com/
TAK | News | $13.38 0.15% 0.9% 1.7M
|
Health Technology
|
| O: -0.17%
H: 0.0%
C: -1.11%
JNJ | News | $149.56 0.3% 0.0% 9.1M
|
Health Technology
|
| O: 0.5%
H: 0.36%
C: -0.86%
ARCT 4 | $27.93 3.22% 3.11% 310K
|
Health Technology
|
| O: 1.81%
H: 2.1%
C: -0.32%
phase 2 vaccine phase 3 approval sars-cov-2
COVID-19 Vaccine Developed by Clover Biopharmaceuticals Using Dynavax's CpG 1018 Adjuvant Meets Primary and Secondary Efficacy Endpoints in Global Phase 2/3 Trial
Published: 2021-09-22 (Crawled : 11:00) - prnewswire.com
DVAX | $11.75 -0.76% -0.77% 1.4M
|
Health Technology
|
| O: 6.33%
H: 30.76%
C: 18.92%
covid phase 2 biopharma phase 2/3 vaccine trial
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.